AtriCure (ATRC) concentration risks

AtriCure's concentration risk spans supply, product, and distribution. On the supply side, the company relies on single and limited source third-party vendors for the manufacture and sterilization of components used in its products — a high-size dependency exposure that leaves limited room to quickly substitute suppliers if one relationship were disrupted. On the product side, ablation and LAAM products are expected to continue accounting for a majority of revenue for the foreseeable future, a medium-size structural exposure reflecting the company's core commercial focus rather than a counterparty-specific risk. On the distribution side, the company depends on independent third-party distributors to sell its products in certain markets outside the United States, and underperformance by these distributors could limit international revenue growth — a low-size dependency exposure. Taken together, the supply-side vendor dependency is the most consequential of the three given its high disclosed size, since a disruption there could affect production across the ablation and LAAM lines that already carry concentrated revenue reliance. The distributor dependency, by contrast, is the smallest of the three and mainly caps upside in specific international markets rather than threatening the core business.

For the engine’s reasoning on ATRC’s current verdict — including which dimensions drove the score — see the per-dimension breakdown.

Concentration counts reflect items disclosed in each peer’s most recent 10-K; disclosed-size classification uses TrendMatrix’s internal 10-K extraction taxonomy.